Pfizer Inc., Eli Lilly & Co. and eight other large drugmakers will partner with the U.S. government in a $230 million effort to identify new approaches to treat Alzheimer’s, diabetes, lupus and arthritis.
As business and political leaders gather in Davos this week, those weary of the palaver on trade alliances, mergers and charity initiatives can stop by the Congress Centre on Thursday morning. There, Goldie Hawn will expound on the benefits of meditation.
When Chris Viehbacher , the chief executive of Paris-based drugmaker Sanofi-Aventis SA , was trying to keep details of his unsolicited bid last year for Genzyme Corp. under wraps, he couldn’t resist drawing on his beloved Bordeaux.
Merck & Co. is putting the prevailing theory on the cause of Alzheimer’s to a test with two studies in thousands of people that may, once and for all, determine whether the amyloid tangles that grow in the brain spur the disease or are simply an outgrowth.
Sanofi Chief Executive Officer Chris Viehbacher said the French drugmaker will return to earnings growth in the fourth quarter after the loss of patent protection on nine drugs in the past three years eroded profit.